67-6

43/93

‥‥‥‥‥‥(years)Pilocytic astrocytoma(WHO Ⅰ)Oligodendroglioma(WHO Ⅱ)Diffuse astrocytoma(WHO Ⅱ)AnaplasticOligodendroglioma(WHO Ⅲ)Anaplasticastrocytoma(WHO Ⅲ)Glioblastoma(WHO Ⅳ)Ependymoma(WHO Ⅰ-Ⅲ)Table 2　Major Prognostic Biomarkers of brain tumors (modified from reference 17)encourage the use of such drugs. For example, if a patient requests it, the government will allow the use of the relevant drug even if it is not covered by insurance, or the drug company may provide the drug for free. Society as a whole is becoming ready to promote this kind of medicine.It is also necessary to promote the development of more such drugs in parallel.We have summarized the recent developments in central nervous system tumors and genomic medicine. Currently, the most important is the development of therapies that follow these tests. Even if genetic abnormalities can be identified, there is an absolute lack of drugs and medical tools to correct them. I sincerely hope that all of you with young and flexible minds will propose new treatments in this field through your research.Author contributionsAK planned this manuscript, collected the neces-sary literature information, analyzed them carefully, and drafted the manuscript. He has thoroughly reviewed and approved the final version of the manuscript for publication.Median agoAt diagnosis5 yearSurvival1243485053645-5%4510 yearprognosticbiomarkersrate＞90％94％65％81％40％50％43％57％20%30%NA83%Close to 80% 1) Dunbar EM， Eppolito A， Henson JW： Genetic counseling and tumor predisposition in neuro-oncology practice. Neuro-Oncology Practice. 2016; 3: 17-28. 2) Reilly KM: Brain tumor susceptibility: the role of genetic factors and uses of mouse models to unravel risk. Brain Pathol. 2009; 19: 121-131. 3) https://www.ambrygen.com/patients/understand- more/brain-cancer. 4) Fukushima Y, Kamatani N, Kosugi S et al: Guidelines for Genetic Tests and Diagnoses in Medical Practice” The Japanese Association of Medical Sciences. February 18, 2011. 5) Aitken M, Kleinrock M, Simorellis A et al: Global Oncology Trends 2018. Institute Report May 24, 2018. 6) Buffery D : Innovation Tops Current Trends in the 2016 Oncology Drug Pipeline. Am Health Drug Bene-fits. 2016; 9: 233-238. 7) Frampton GM, Fichtenholtz A, Otto GA et al: Develop-ment and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotech. 2013; 31: 1023-1033. 8) Mossé YP, Wood A, Maris JM: Inhibition of ALK signaling for cancer therapy. Clin Cancer Res. 2009; 15: 5609-5614. 9) Hovelson DH, McDaniel AS, Cani AK et al: Develop-ment and validation of a scalable next-generation sequencing system for assessing relevant somatic vari-ants in solid tumors. Neoplasia. 2015; 17: 385-399.10) Roma-Rodrigues C, Rivas-García L, Baptista PV et al: Gene Therapy in Cancer Treatment: Why Go Nano? The author declares that there are no conflicts of interest.Major favorableprognosticbiomarkersBRAF-KIAA1549fusionIDH1/2-mutation1p/19q codeletionIDH1/2-mutationIDH1/2-mutation1p/19q codeletionIDH1/2-mutationMGMT methylationIDH1/2-mutationMGMT methylationMajor negativeprognosticbiomarkersH3 K27M-mutationRELA-fusion positiveGain of chromosomearm 1q551ConclusionConflicts of interestReferences